Skip to main content
. Author manuscript; available in PMC: 2014 May 15.
Published in final edited form as: Cancer Res. 2013 May 3;73(10):3075–3086. doi: 10.1158/0008-5472.CAN-12-2357

Figure 4.

Figure 4

ALT-803 did not increase expression maturation markers on BM dendritic cells. Female C57BL/6NHsd mice (5–6 weeks-old, 3 mice/group) were untreated (normal) or injected i.v. with 5T33P myeloma cells (1 × 107/mouse) (5T33P-bearing) on day 0. ALT-803 (0.2 mg/kg) or PBS (dose volume equivalent) was administered i.v. on day 14. Four days after treatment, BM cells were isolated, pooled and stained with Abs specific to CD11c (PE-Cy7), MHC II [I-A(b)] (FITC), CD80 (PerCP-Cy5.5), and CD40 (APC), then analyzed by flow cytometry. Mice treated i.p. either with 12.5 μg of LPS (E. coli 055:B5, Sigma-Aldrich) and sacrificed 12 hrs later or with 10 μg of Poly IC (InvivoGene) and sacrificed 24 hrs later served as positive controls. Histograms show staining with positive Abs (black line) or isotype controls (gray line).